FDA Approves Lyrfigtu (Lirafugratinib) for the Treatment of Cholangiocarcinoma by Madaline Spencer| Published on: Sep 29, 2026

https://checkrare.com/fda-approves-lyrfigtu-lirafugratinib-for-the-treatment-of-cholangiocarcinoma/ The US Food and Drug Administration (FDA) has approved Lyrfigtu (lirafugratinib) for the treatment of cholangiocarcinoma with FGFR2 fusion or other rearrangement. Cholangiocarcinoma is a rare, aggressive cancer that forms in the bile duct. Patients with cholangiocarcinoma are often diagnosed at a later stage when the prognosis is poor. The disease can be classified based on whether the cancer is in the bile duct within the liver (intrahepatic cholangiocarcinoma [iCCA]) or outside the liver (extrahepatic cholangiocarcinoma).